JP2009538276A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538276A5
JP2009538276A5 JP2009507606A JP2009507606A JP2009538276A5 JP 2009538276 A5 JP2009538276 A5 JP 2009538276A5 JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009538276 A5 JP2009538276 A5 JP 2009538276A5
Authority
JP
Japan
Prior art keywords
deoxynojirimycin
pentane
neopentyloxy
methoxy
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009507606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2007/050177 external-priority patent/WO2007123403A1/en
Publication of JP2009538276A publication Critical patent/JP2009538276A/ja
Publication of JP2009538276A5 publication Critical patent/JP2009538276A5/ja
Ceased legal-status Critical Current

Links

JP2009507606A 2006-04-24 2007-04-24 嚢胞性線維症の改良型治療 Ceased JP2009538276A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79408806P 2006-04-24 2006-04-24
PCT/NL2007/050177 WO2007123403A1 (en) 2006-04-24 2007-04-24 Improved treatment of cystic fibrosis

Publications (2)

Publication Number Publication Date
JP2009538276A JP2009538276A (ja) 2009-11-05
JP2009538276A5 true JP2009538276A5 (https=) 2010-04-08

Family

ID=38283020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507606A Ceased JP2009538276A (ja) 2006-04-24 2007-04-24 嚢胞性線維症の改良型治療

Country Status (10)

Country Link
US (1) US8410081B2 (https=)
EP (1) EP2010551B1 (https=)
JP (1) JP2009538276A (https=)
CN (1) CN101479288B (https=)
AT (1) ATE479696T1 (https=)
AU (1) AU2007241622A1 (https=)
BR (1) BRPI0710883A2 (https=)
CA (1) CA2650311A1 (https=)
DE (1) DE602007008870D1 (https=)
WO (1) WO2007123403A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CA2753195C (en) 2009-02-23 2015-06-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
ES2562635T3 (es) * 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus
CN102639133B (zh) 2009-06-12 2015-03-11 联合治疗公司 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法
WO2011028779A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
CN102625801B (zh) * 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
KR101497194B1 (ko) * 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
PL2854910T3 (pl) 2012-06-01 2020-07-27 Icahn School Of Medicine At Mount Sinai Poziomy ceramidu w leczeniu i zapobieganiu infekcjom
US20150346185A1 (en) * 2012-12-05 2015-12-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Diagnosis of cystic fibrosis
CA2905449C (en) 2013-03-14 2024-09-10 Icahn School Of Medicine At Mount Sinai THERAPEUTIC COMPOSITIONS OF ACID CERAMIDASE AND THEIR PROCESSES OF MANUFACTURE AND USE
US20190142782A1 (en) 2016-04-11 2019-05-16 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
AU2018278247B2 (en) 2017-06-01 2022-07-28 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
AU2022235284A1 (en) * 2021-03-12 2023-10-05 Excepgen Inc. Systems and methods for protein expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
AU5799500A (en) 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2005123055A2 (en) 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof

Similar Documents

Publication Publication Date Title
JP2009538276A5 (https=)
JP2004519469A5 (https=)
JP2004538303A5 (https=)
JP2011513196A5 (https=)
JP2010504343A5 (https=)
HRP20150277T1 (hr) Modulatori atp-vezujuä†ih kasetnih transportera
JP2007016035A5 (https=)
JP2006526590A5 (https=)
JP2010502730A5 (https=)
JP2010528011A5 (https=)
JP2007514005A5 (https=)
JP2009535307A5 (https=)
JP2012502885A5 (https=)
JP2008539268A5 (https=)
JP2014508804A5 (https=)
JP2009500423A5 (https=)
JP2010511631A5 (https=)
WO2009064374A8 (en) Oral formulations of bis(thiohydrazide amides)
ES2489265T3 (es) Asociación de inhibidores de la HMG-CoA reductasa atorvastatina o simvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast para el tratamiento de enfermedades pulmonares inflamatorias
JP2008546770A5 (https=)
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
JP2000159790A5 (https=)
JP2008515980A5 (https=)
JP2011068692A5 (https=)
EA200500240A1 (ru) Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой